The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Interfering with disease: a progress report on siRNA-based therapeutics
Open accessAbstract
RNA interference (RNAi) quietly crept into biological research in the 1990s when unexpected gene-silencing phenomena in plants and flatworms first perplexed scientists. Following the demonstration of RNAi in mammalian cells in 2001, it was quickly realized that this highly specific mechanism of sequence-specific gene silencing might be harnessed to develop a new class of drugs that interfere with disease-causing or disease-promoting genes. Here we discuss the considerations that go into developing RNAi-based therapeutics starting from in vitro lead design and identification, to in vivo pre-clinical drug delivery and testing. We conclude by reviewing the latest clinical experience with RNAi therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
TOLENTINO, M. J., BRUCKER, A. J., FOSNOT, J., YING, G.-S., WU, I.-H., MALIK, G., WAN, S., & REICH, S. J. (2004) · RETINA · doi:10.1097/00006982-200402000-00018 · Cited by 172
RetractedSuppression of Discoidin Domain Receptor 1 by RNA Interference Attenuates Lung Inflammation
Matsuyama, W., Watanabe, M., Shirahama, Y., Hirano, R., Mitsuyama, H., Higashimoto, I., Osame, M., & Arimura, K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1928 · Cited by 39
RetractedPotent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
MicroRNAs: small RNAs with a big role in gene regulation
He, L., & Hannon, G. J. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1379 · Cited by 7,118
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
Asymmetry in the Assembly of the RNAi Enzyme Complex
Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922
Functional siRNAs and miRNAs exhibit strand bias
Khvorova, A., Reynolds, A., & Jayasena, S. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00801-8 · Cited by 2,645
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370
Cited by
Activatable Photosensitizers for Imaging and Therapy
Lovell, J. F., Liu, T. W. B., Chen, J., & Zheng, G. (2010) · Chemical Reviews · doi:10.1021/cr900236h · Cited by 1,717
The evolution of gene regulation by transcription factors and microRNAs
Chen, K., & Rajewsky, N. (2007) · Nature Reviews Genetics · doi:10.1038/nrg1990 · Cited by 1,547
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
Functional Repression of cAMP Response Element in 6-Hydroxydopamine-treated Neuronal Cells
Chalovich, E. M., Zhu, J.-H., Caltagarone, J., Bowser, R., & Chu, C. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602632200 · Cited by 1,371
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Self-citationJackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Yao, J., Yang, M., & Duan, Y. (2014) · Chemical Reviews · doi:10.1021/cr200359p · Cited by 944
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics
Heitz, F., Morris, M. C., & Divita, G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00057.x · Cited by 867
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., & Hermeking, H. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6533 · Cited by 784
Subcellular targeting strategies for drug design and delivery
Rajendran, L., Knölker, H.-J., & Simons, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2897 · Cited by 708
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
Scales, S. J., & de Sauvage, F. J. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.007 · Cited by 650
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex
Wang, Y., Juranek, S., Li, H., Sheng, G., Tuschl, T., & Patel, D. J. (2008) · Nature · doi:10.1038/nature07666 · Cited by 577
Strategies, design, and chemistry in siRNA delivery systems
Dong, Y., Siegwart, D. J., & Anderson, D. G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.004 · Cited by 572
Structure of the guide-strand-containing argonaute silencing complex
Wang, Y., Sheng, G., Juranek, S., Tuschl, T., & Patel, D. J. (2008) · Nature · doi:10.1038/nature07315 · Cited by 543
Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.027 · Cited by 546
Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes
Wang, Y., Juranek, S., Li, H., Sheng, G., Wardle, G. S., Tuschl, T., & Patel, D. J. (2009) · Nature · doi:10.1038/nature08434 · Cited by 542
Zhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
Mui, B. L., Tam, Y. K., Jayaraman, M., Ansell, S. M., Du, X., Tam, Y. Y. C., Lin, P. J., Chen, S., Narayanannair, J. K., Rajeev, K. G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.66 · Cited by 505
Hermeking, H. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.028 · Cited by 494
microRNAs and the immune response
Lindsay, M. A. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.04.004 · Cited by 475
Nonviral delivery of synthetic siRNAs in vivo
Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464
miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial Cells
Würdinger, T., Tannous, B. A., Saydam, O., Skog, J., Grau, S., Soutschek, J., Weissleder, R., Breakefield, X. O., & Krichevsky, A. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.005 · Cited by 463
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer
Bellahcène, A., Castronovo, V., Ogbureke, K. U. E., Fisher, L. W., & Fedarko, N. S. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2345 · Cited by 454
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Zhu, C., Jung, S., Luo, S., Meng, F., Zhu, X., Park, T. G., & Zhong, Z. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.077 · Cited by 440
Chemically modified siRNA: tools and applications
Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
Layer-by-Layer Assembled Gold Nanoparticles for siRNA Delivery
Elbakry, A., Zaky, A., Liebl, R., Rachel, R., Goepferich, A., & Breunig, M. (2009) · Nano Letters · doi:10.1021/nl9003865 · Cited by 425
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 424
Nanoparticles and their applications in cell and molecular biology
Wang, E. C., & Wang, A. Z. (2014) · Integrative Biology · doi:10.1039/c3ib40165k · Cited by 415
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387
Recent advances in siRNA delivery mediated by lipid-based nanoparticles
Yonezawa, S., Koide, H., & Asai, T. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.022 · Cited by 378
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane
Zuckerman, J. E., Choi, C. H. J., Han, H., & Davis, M. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200718109 · Cited by 372
A review of nanocarriers for the delivery of small interfering RNA
Kesharwani, P., Gajbhiye, V., & Jain, N. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.068 · Cited by 368
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Chen, S., Tam, Y. Y. C., Lin, P. J. C., Sung, M. M. H., Tam, Y. K., & Cullis, P. R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.059 · Cited by 366
Cell‐penetrating peptides: from molecular mechanisms to therapeutics
Morris, M. C., Deshayes, S., Heitz, F., & Divita, G. (2008) · Biology of the Cell · doi:10.1042/bc20070116 · Cited by 361
Loh, C.-Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00048 · Cited by 348
A New Potent Secondary Amphipathic Cell–penetrating Peptide for siRNA Delivery Into Mammalian Cells
Crombez, L., Aldrian-Herrada, G., Konate, K., Nguyen, Q. N., McMaster, G. K., Brasseur, R., Heitz, F., & Divita, G. (2009) · Molecular Therapy · doi:10.1038/mt.2008.215 · Cited by 346
Targeting of tetraspanin proteins — potential benefits and strategies
Hemler, M. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2659 · Cited by 345
Eguchi, A., Meade, B. R., Chang, Y.-C., Fredrickson, C. T., Willert, K., Puri, N., & Dowdy, S. F. (2009) · Nature Biotechnology · doi:10.1038/nbt.1541 · Cited by 340
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Taratula, O., Garbuzenko, O. B., Kirkpatrick, P., Pandya, I., Savla, R., Pozharov, V. P., He, H., & Minko, T. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.019 · Cited by 328
Matsumoto, S., Christie, R. J., Nishiyama, N., Miyata, K., Ishii, A., Oba, M., Koyama, H., Yamasaki, Y., & Kataoka, K. (2009) · Biomacromolecules · doi:10.1021/bm800985e · Cited by 327
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening
Silva, J. M., Marran, K., Parker, J. S., Silva, J., Golding, M., Schlabach, M. R., Elledge, S. J., Hannon, G. J., & Chang, K. (2008) · Science · doi:10.1126/science.1149185 · Cited by 318
Nanomaterials for Cancer Therapy and Imaging
Bae, K. H., Chung, H. J., & Park, T. G. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0051-5 · Cited by 313
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Sato, Y., Hatakeyama, H., Sakurai, Y., Hyodo, M., Akita, H., & Harashima, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.009 · Cited by 309
Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3847 · Cited by 306
Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides
Juliano, R., Bauman, J., Kang, H., & Ming, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900093r · Cited by 304
EL Andaloussi, S., Lehto, T., Mäger, I., Rosenthal-Aizman, K., Oprea, I. I., Simonson, O. E., Sork, H., Ezzat, K., Copolovici, D. M., Kurrikoff, K., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1299 · Cited by 301
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
Self-citationLim, J.-M., Swami, A., Gilson, L. M., Chopra, S., Choi, S., Wu, J., Langer, R., Karnik, R., & Farokhzad, O. C. (2014) · ACS Nano · doi:10.1021/nn501371n · Cited by 297
Nano-based delivery of RNAi in cancer therapy
Xin, Y., Huang, M., Guo, W. W., Huang, Q., Zhang, L. Z., & Jiang, G. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0683-y · Cited by 295
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
Cell-Penetrating Peptides—Mechanisms of Cellular Uptake and Generation of Delivery Systems
Trabulo, S., Cardoso, A. L., Mano, M., & De Lima, M. C. P. (2010) · Pharmaceuticals · doi:10.3390/ph3040961 · Cited by 290
Polyelectrolyte microcapsules for biomedical applications
De Geest, B. G., De Koker, S., Sukhorukov, G. B., Kreft, O., Parak, W. J., Skirtach, A. G., Demeester, J., De Smedt, S. C., & Hennink, W. E. (2009) · Soft Matter · doi:10.1039/b808262f · Cited by 289
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
Nanotechnology and aptamers: applications in drug delivery
Levy-Nissenbaum, E., Radovic-Moreno, A. F., Wang, A. Z., Langer, R., & Farokhzad, O. C. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.04.006 · Cited by 270
Wang, T., Upponi, J. R., & Torchilin, V. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.013 · Cited by 268
Macrophages, Chronic Inflammation, and Insulin Resistance
Li, H., Meng, Y., He, S., Tan, X., Zhang, Y., Zhang, X., Wang, L., & Zheng, W. (2022) · Cells · doi:10.3390/cells11193001 · Cited by 264
Huschka, R., Barhoumi, A., Liu, Q., Roth, J. A., Ji, L., & Halas, N. J. (2012) · ACS Nano · doi:10.1021/nn301135w · Cited by 264
Advanced in developmental organic and inorganic nanomaterial: a review
Khalid, K., Tan, X., Mohd Zaid, H. F., Tao, Y., Lye Chew, C., Chu, D.-T., Lam, M. K., Ho, Y.-C., Lim, J. W., & Chin Wei, L. (2020) · Bioengineered · doi:10.1080/21655979.2020.1736240 · Cited by 263
Du, X., Li, X., Xiong, L., Zhang, X., Kleitz, F., & Qiao, S. Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.019 · Cited by 262
MMP9: A Tough Target for Targeted Therapy for Cancer
Augoff, K., Hryniewicz-Jankowska, A., Tabola, R., & Stach, K. (2022) · Cancers · doi:10.3390/cancers14071847 · Cited by 255
Hatakeyama, H., Ito, E., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S., & Harashima, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.008 · Cited by 254
Nonviral methods for siRNA delivery
Gao, K., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800134q · Cited by 244
Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape
Endoh, T., & Ohtsuki, T. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.005 · Cited by 242
Yang, Y., Liu, F., Liu, X., & Xing, B. (2013) · Nanoscale · doi:10.1039/c2nr32835f · Cited by 229
Advances in lipid nanoparticles for siRNA delivery
Tam, Y., Chen, S., & Cullis, P. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5030498 · Cited by 229
Zhu, L., Perche, F., Wang, T., & Torchilin, V. P. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.060 · Cited by 220
Yang, T., Fogarty, B., LaForge, B., Aziz, S., Pham, T., Lai, L., & Bai, S. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0015-y · Cited by 204
MicroRNAs in neurodegenerative diseases and their therapeutic potential
Junn, E., & Mouradian, M. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.10.002 · Cited by 186
In vivo delivery of RNAi with lipid-based nanoparticles
Huang, L., & Liu, Y. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124709 · Cited by 174
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie · doi:10.1002/ange.201203263 · Cited by 150
Common themes in siRNA-mediated epigenetic silencing pathways
Verdel, A., Vavasseur, A., Le Gorrec, M., & Touat-Todeschini, L. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.082691av · Cited by 135
Closed Chromatin Architecture Is Induced by an RNA Duplex Targeting the HIV-1 Promoter Region
Suzuki, K., Juelich, T., Lim, H., Ishida, T., Watanebe, T., Cooper, D. A., Rao, S., & Kelleher, A. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709651200 · Cited by 108
Versatile RNA Interference Nanoplatform for Systemic Delivery of RNAs
Choi, K. Y., Silvestre, O. F., Huang, X., Min, K. H., Howard, G. P., Hida, N., Jin, A. J., Carvajal, N., Lee, S. W., Hong, J.-I., et al. (2014) · ACS Nano · doi:10.1021/nn500085k · Cited by 104
Miyake, M., Ishii, M., Kawashima, K., Kodama, T., Sugano, K., Fujimoto, K., & Hirao, Y. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00543.x · Cited by 79
Takahashi, H., Wang, Y., & Grainger, D. W. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.019 · Cited by 58
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
Naik, S., Shreya, A. B., Raychaudhuri, R., Pandey, A., Lewis, S. A., Hazarika, M., Bhandary, S. V., Rao, B. S. S., & Mutalik, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118712 · Cited by 33
The potential of RNA interference-based therapies for viral infections
Huang, D. D. (2008) · Current HIV/AIDS Reports · doi:10.1007/s11904-008-0006-4 · Cited by 20
Metadata
- Authors
- de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-06
- Volume
- 6
- Issue
- 6
- Pages
- 443-453
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2166915947
- Cited by
- 1,203
- References
- 104
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.